Aim: While propranolol hydrochloride (PH) is being more widely used in adults, its administration in the very preterm infants as well is progressively on the rise in our time. With the increasing use of PH in the neonatal period, worries resulting from the potential adverse effects of the agent on organs, such as brain in particular, have come to the fore. Such concerns increase even more when PH is used in treating infants. Our study, aiming to clarify these increasing concerns, is the first clinical one of its kind in the literature, conducted on preterm infants, the patient group most vulnerable to PH.
Metods: This was a double-blind, randomized, and placebo-controlled trial. The gestational age of all infants in the study was below 31+6 weeks, and their birth weight was under 1500g.At approximately one year of age, the Ankara Developmental Screening Inventory and the Denver Developmental Screening Test-II were used to assess the mental development of the children.
Results: In the PHG patients, PH treatment was initiated at 27.0±2.7 days of life and lasted for 26.5±8.7days.The subjects in the control group received placebo. No statistically significant difference was found between the groups in terms of physical and mental development of the infants (p>0.05).
Conclusions: When used on preterm infants, PH may have some temporary effects on the patients’ functions in the short term; however, no serious side effects were detected that may affect the physical and mental development in the long run.